**Name of Journal:** *World Journal of Meta-Analysis*

**Manuscript No:** 54481

**Manuscript Type:** REVIEW

**Immunotherapy in hepatocellular carcinoma: Combination strategies**

Jordan AC *et al*. Immunotherapy in hepatocellular carcinoma

Alexander Claudius Jordan, Jennifer Wu

**Alexander Claudius** **Jordan,** Department of Internal Medicine, New York University School of Medicine**,** New York, NY 10016, United States

**Jennifer Wu,** Division of Hematology and Oncology,Perlmutter Cancer Center, New York University Langone Medical Center, New York, NY 10016, United States

**Author contributions:** Jordan AC wrote and edited the manuscript; Wu J reviewed and edited the manuscript.

**Corresponding author: Jennifer Wu, MD, Associate Professor,** Division of Hematology and Oncology,Perlmutter Cancer Center, New York University Langone Medical Center, 550 1st Avenue, New York, NY 10016, United States. jennifer.wu@nyulangone.org

**Received:** February 1, 2020

**Revised:** May 1, 2020

**Accepted:** June 25, 2020

**Published online:**

**Abstract**

Liver cancer is one of the most common causes of cancer death globally, and its incidence in the United States is increasing. Patients with advanced hepatocellular carcinoma (HCC) who are not candidates for surgical resection, liver transplant, or locoregional therapies can be treated with systemic therapies. Multiple agents, including sorafenib, lenvatinib, and regorafenib are approved for use as either first- or second-line therapy in this patient population, but all have relatively modest survival benefits. HCC is potentially susceptible to therapy with checkpoint inhibitors, including agents such as nivolumab and pembrolizumab, which are both approved by the Food and Drug Administration for patients previously treated with sorafenib but have not demonstrated superior overall survival in phase III trials. It is clear that more effective approaches are needed to potentiate the effects of checkpoint inhibitors in patients with HCC. This review will outline and appraise the current literature on the use of checkpoint inhibitors in HCC as part of a combination treatment involving an additional mode of therapy.The list of agents that can be paired with checkpoint inhibitors includes an additional checkpoint inhibitor, vascular endothelial growth factor or vascular endothelial growth factor receptor inhibitors, tyrosine kinase inhibitors, OX-40 agonists, and PT-112 inhibitors. The main non-pharmacologic therapies currently being studied for inclusion in a combination strategy include radiation therapy, trans-arterial chemoembolization, and ablation.

**Key words:** Hepatocellular carcinoma; Liver neoplasms; Antineoplastic agents; Immunological; Protein kinase inhibitors; Angiogenesis inhibitors

Jordan AC, Wu J. Immunotherapy in hepatocellular carcinoma: Combination strategies. *World J Meta-Anal* 2020; In press

**Core tip:**Immunotherapy remains a viable option for the systemic treatment of patients with unresectable hepatocellular carcinoma, although nivolumab and pembrolizumab failed to meet their endpoints in phase III studies. Combining immunotherapy with other treatment modalities may improve treatment responses. Multiple clinical trials are evaluating the safety and efficacy of these new combination strategies, which involve pairing PD-1 or PD-L1 inhibitors with CTLA-4 inhibitors, or pairing checkpoint inhibitors with alternative agents or non-pharmacologic therapies.

**INTRODUCTION**

Worldwide, liver cancer is the fourth leading cause of cancer death and the seventh most common cancer in terms of incidence[1]. The most common liver cancer subtype is hepatocellular carcinoma[1]. Over the last 40 years, hepatocellular carcinoma (HCC) incidence has risen by approximately three-fold in the Unite States[2]. Between 2000 and 2009, the incidence rose by approximately 4.5% per year and 0.7% per year from 2010 to 2012[3].Between the years 2018 and 2040, global liver cancer incidence is expected to rise by approximately 62%, while the number of liver cancer deaths worldwide will rise by 64%[2]. If HCC is detected at an early stage (Barcelona Clinic Liver Cancer stage 0 or A), surgical resection or ablation can be performed in select groups of patients[4]. Approximately 70% of patients will develop evidence of recurrence following resection[4,5]. If patients are not candidates for surgical resection, liver transplantation is offered to patients who meet the Milan criteria and provides a possibility of cure[4,5]. Patients who are not eligible for surgery or liver transplantation are candidates for locoregional therapies, including trans-arterial chemoembolization (TACE) and ablation, if they have early- or intermediate-stage disease (Barcelona Clinic Liver Cancer stage 0-B), or systemic therapies if they have advanced disease (Barcelona Clinic Liver Cancer stage C)[4]. Multiple options for systemic therapy exist (Table 1). The tyrosine kinase inhibitors sorafenib and lenvatinib are approved for use as first-line therapy[6].Ramucirumab, a monoclonal antibody directed against vascular endothelial growth factor (VEGF) receptor 2, and the tyrosine kinase inhibitors regorafenib and cabozantinib are approved for patients previously treated with sorafenib, however, candidates for ramucirumab therapy must also have an alpha-fetoprotein (AFP) level of 400 ng/mL or greater[6,7].With the exception of lenvatinib, which produced an objective response rate (ORR) of 24.1%, the rest of the approved systemic therapies could only achieve an ORR in the range of 2 to 11%[8-12]. Sorafenib, ramucirumab, regorafenib and cabozantinib were directly compared to placebo and increased overall survival by only 1.2 to 2.8 mo[8,10-12].

In hopes of discovering therapies that could produce greater responses, investigators began to utilize checkpoint inhibitors in HCC patients, given their success in other malignancies and the contribution of the PD-1/PD-L1 and CTLA4 pathways to creating an immunosuppressive tumor microenvironment[13-15] (Table 2).Nivolumab demonstrated an ORR of 15% and 20% in the dose-escalation and dose-expansion phases of the CheckMate 040 trial, respectively, while pembrolizumab produced an ORR of 17% in the KEYNOTE-224 trial[13,14].Both agents were then Food and Drug Administration (FDA)-approved for use in patients who had previously received sorafenib[16,17].However, neither nivolumab or pembrolizumab demonstrated a statistically significant improvement in overall survival (OS) in patients with unresectable HCC when compared to sorafenib or placebo in phase III trials, respectively[18,19]. Other checkpoint inhibitors studied in HCC patients in completed phase II trials include the PD-1 inhibitors camrelizumab, the PD-L1 inhibitor durvalumab, and the CTLA4 inhibitor tremelimumab[20-22].In a phase II multicenter study (NCT02989922) involving 217 patients from Chinese medical centers with HCC who had failed or could not tolerate prior systemic therapy who were treated with camrelizumab, the ORR was 13.8%, with a six-month OS rate of 74.7%[20].Durvalumab demonstrated an ORR of 10.3% with a median OS of 13.2 mo in a multi-center phase I/II study in a cohort of 40 patients with HCC, most of whom had received prior sorafenib[21]. In a phase II study of tremelimumab in 21 patients from Spanish medical centers with advanced HCC and chronic hepatitis C virus (HCV) infection, the ORR was 17.6% with a median OS of 8.2 mo[22]. Tremelimumab caused a decrease in AFP levels of more than 50% in slightly more than one-third of all patients, and a reduction in HCV viral load in most patients[22].

The relatively modest benefits of currently-available systemic therapies for patients with advanced or unresectable HCC underscore the need for novel and improved therapies. Although nivolumab and pembrolizumab did not reach their endpoints in phase III trials, checkpoint inhibitors in general remain the focus of multiple active trials[18,19] (Tables 3-6).Updated results from the KEYNOTE-224 trial demonstrated that median OS was much greater in patients who responded to pembrolizumab compared to non-responders at the time of the first post-treatment scan, and that 30.8% of patients were alive at a median follow-up of 31.2 mo[23].These results suggest that patients who respond to checkpoint inhibitors may have a durable response. Combination therapies involving the use of both a checkpoint inhibitor and another therapy may provide a greater benefit than single-agent immunotherapy if they can substantially improve overall response rates.This review will outline the main types of combination therapies currently under investigation, discuss the rationale behind their design, and summarize the main clinical trials evaluating their safety and efficacy in HCC patients.

**COMBINATION THERAPY WITH PD-1/PD-L1 INHIBITORS PLUS CTLA-4 INHIBITORS**

The combination of nivolumab plus ipilimumab has proven successful in improving treatment responses in multiple malignancies when compared to standard-of-care therapy[24-27]. As a first line regimen, the combination of nivolumab and ipilimumab has demonstrated superior ORR, OS, and progression-free survival (PFS) when compared to either agent alone in patients with metastatic melanoma, even after 48 mo of median follow-up[24,28]. Given what is known regarding the immune microenvironment of HCC, these results raised the question about whether or not the combination of a PD-1 inhibitor and CTLA-4 inhibitor can demonstrate durable clinical responses in advanced HCC patients that are superior to those seen with single-agent checkpoint inhibitors or targeted therapies in HCC patients.

***Nivolumab plus ipilimumab***

The CheckMate 040 study (NCT01658878) randomized 148 HCC patients who were previously treated with sorafenib to three separate arms comparing various treatment regimens utilizing ipilimumab and nivolumab[29,30]. Patients in Arm A received nivolumab 1 mg/kg plus ipilimumab 3 mg/kg every three weeks for four doses followed by nivolumab 240 mg every two weeks, patients in Arm B received nivolumab 3 mg/kg plus ipilimumab 1 mg/kg every three weeks for four doses followed by nivolumab 240 mg every two weeks, and patients in Arm C received nivolumab 3 mg/kg every two weeks plus ipilimumab 1 mg/kg given every six weeks[29]. Initial results indicated that 37% of patients developed grade 3 or 4 toxicity, with rash and pruritus being the most frequently reported adverse effect[29]. The ORR was 31%, and after 24 mo of follow-up, the OS rate was 40%[29]. This study was updated at the International Liver Cancer Association Conference in Sep 2019[31]. All 3 arms achieved a similar ORR (Arm A - 32%, Arm B - 31% and Arm C - 31%), while Arm A achieved the longest median OS (22.8 mo *vs* 12.5 mo for Arm B and 12.7 mo for Arm C) and the highest OS rate at 30 mo (44%)[31] (Table 2). The study remains active[30].

The rather innovative study design allowed investigators to compare the impact of various doses of nivolumab and ipilimumab on treatment response[29-31]. The dosing schedule in Arms A and B was similar, however, the dose of ipilimumab was three times higher in Arm A, and patients in Arm C received ipilimumab less frequently than the other two arms[29]. The higher dose of ipilimumab received by patients in Arm A compared to patients in Arms B or C may have been responsible for the improved median overall survival[29]. Unsurprisingly, Arm A also had the highest number of treatment-related adverse effects, possibly due to the larger doses of ipilimumab the patients received, highlighting the inherent toxicity of this combination[31]. Twenty-two percent of patients discontinued the combination due to drug-related adverse events, compared to 6% and 2% of patients in Arms B and C, respectively[31]. Based on the results of CheckMate 040, the FDA has granted a priority review for nivolumab plus ipilimumab in the treatment of patients with advanced HCC who progressed on sorafenib as of November 2019[32].

There are multiple active clinical trials in addition to CheckMate 040 evaluating nivolumab plus ipilimumab for various treatment indications in HCC patients (Table 3). These include the phase III CheckMate 9DW clinical trial (NCT04039607) evaluating nivolumab plus ipilimumab as first-line therapy in comparison to sorafenib or lenvatinib in patients with advanced HCC[33]. The primary endpoint is overall survival[33]. If the combination of nivolumab and ipilimumab demonstrates significantly improved OS compared to standard-of-care sorafenib or lenvatinib, it may become the new standard-of-care first-line therapy. However, the increased toxicity seen with this combination, especially if doses are similar to those used in Arm A of the CheckMate 040 trial, may lead to higher rates of therapy discontinuation[29]. At least three separate studies will evaluate the safety and feasibility of neoadjuvant nivolumab plus ipilimumab administered prior to surgical resection[34-36]. The phase II study (NCT03222076) sponsored by Anderson Cancer Center will randomize 45 patients with resectable HCC to receive adjuvant nivolumab or nivolumab plus ipilimumab prior to resection[34]. If successful, further studies may explore whether neoadjuvant nivolumab plus ipilimumab can decrease the high recurrence rates observed after surgical resection[4,5].

***Durvalumab plus tremelimumab***

The combination of durvalumab and tremelimumab was studied in a phase I/II trial (NCT02519348) in patients with unresectable HCC[37]. The safety profile was deemed tolerable and an ORR of 15% was noted, according to results from the phase I portion of the study[37] (Table 2). Common adverse effects included pruritus, fatigue, and elevated transaminases, which are similar to those noted in patients treated with durvalumab in phase II studies[21,37]. The phase II portion of the study seeks to evaluate the safety and feasibility of durvalumab plus tremelimumab as second-line therapy[38] (Table 3). This study will randomize 433 patients into five separate arms, in which patients with advanced HCC will receive either durvalumab or tremelimumab alone, durvalumab plus tremelimumab, or durvalumab plus bevacizumab[38]. Two arms of the study will compare different regimens of durvalumab plus tremelimumab[38]. Additional active studies involving this combination include the phase III HIMALAYA clinical trial (NCT03298451) which will compare durvalumab plus tremelimumab to sorafenib or durvalumab alone as first-line therapy in approximately 1310 advanced HCC patients from multiple countries[39] (Table 3). Overall survival is the primary endpoint[39].

It remains to be seen whether the combination of durvalumab plus tremelimumab will have a similar toxicity profile as nivolumab plus ipilimumab. If durvalumab plus tremelimumab can demonstrate a high ORR with a comparatively lower rate of immune-related adverse effects, then it may become a viable alternative for HCC patients who have failed prior systemic therapies and cannot tolerate nivolumab plus ipilimumab due to adverse effects. If the dosing schedule utilized in the phase I/II clinical trial (NCT02519348) is adopted, this may minimize toxicity given the relatively infrequent dosing schedule of every four weeks[37].Although the most common side-effects seen in patients treated with either combination include liver function test abnormalities and skin ailments such as pruritus or rash, the CheckMate 040 study demonstrated that 22% of patients discontinued therapy with nivolumab and ipilimumab due to treatment-related toxicity, compared to 7.5% of patients receiving durvalumab and tremelimumab in the NCT02519348 trial[31,37]. Given the ability of tremelimumab to reduce HCV viral loads, this combination may be preferred for patients with chronic hepatitis C infections[22].

**COMBINATION THERAPY WITH CHECKPOINT INHIBITORS PLUS OX40 AGONISTS**

OX40 is a co-stimulatory receptor that is expressed by CD4 and CD8+ T-cells after antigen stimulation[40]. Treg cells can also express OX40[40]. OX40 agonists, which are monoclonal antibodies that bind OX40, induce T-cell expansion and persistence and may be able to suppress Treg activity[40].The clinical use of a monoclonal antibody targeting OX40 was deemed safe following a phase I study (NCT01644968) in 30 patients with various malignancies, with the most common adverse effects including fatigue, rash, lymphopenia, fever, and pruritus[41]. Twelve patients in demonstrated a reduction in the size of at least one individual metastasis[41].

A combination strategy utilizing OX-40 agonists in conjunction with checkpoint inhibitors may be a viable option in the treatment of HCC. PD-1/PDL1 or CTLA4 blockade and OX40 agonism administered together may produce a greater activation of the immune system due to the targeting of distinct pathways. The use of an OX-40 monoclonal antibody in conjunction with an anti-PD-1 monoclonal antibody in mice models of ovarian cancer produced responses that were superior than those from either agent alone[42]. A phase I/II clinical trial (NCT03241173) was performed to determine whether this form of combination therapy is safe and effective in patients with solid malignancies including HCC[43].The study contained three separate arms, including two arms where nivolumab or ipilimumab alone were given with the OX-40 inhibitor INCAGN01949, and another arm where both checkpoint inhibitors and INCAGN01949 were administered together[43]. Results are pending[43].An additional phase I/II trial sponsored by Incyte Biosciences (NCT03126110) is active and is similarly designed to the first trial, but is employing the OX40 agonist INCAGN01876 in patients with solid malignancies, including HCC[43,44] (Table 3).

**COMBINATION THERAPY WITH CHECKPOINT INHIBITORS PLUS Vascular endothelial growth factor OR vascular endothelial growth factor receptor INHIBITORS**

Anti-angiogenic agents have been a focus of research in HCC due to the relatively high vascularity of HCC tumors, however, studies suggest they may also have beneficial effects on the immune system[45-47].VEGF expression can modulate the immune system *via* various mechanisms, leading to immunosuppression[46,47]. VEGF molecules can inhibit leukocyte adherence to the endothelium, inhibit the development of dendritic cells, and promote Treg proliferation[46,47]. The combination of checkpoint inhibitors and VEGF or vascular endothelial growth factor receptor (VEGFR) inhibitors may cause a greater net activation of the immune system than checkpoint inhibitors alone due to the added effect of VEGF inhibition.

***Atezolizumab plus bevacizumab***

Bevacizumab, a VEGF inhibitor, is currently approved for the treatment of multiple malignancies, including metastatic colorectal cancer, non-squamous non-small cell lung cancer, and ovarian cancer[48]. Bevacizumab was studied in a phase II trial in 46 patients with unresectable HCC and treatment resulted in a median PFS of 6.9 mo and an OS rate of 53% at 1 year, 28% at 2 years, and 23% at 3 years[49]. However, 11% of patients developed clinically significant bleeding, including one patient who suffered a variceal bleed that was ultimately fatal[49].Another phase II study evaluating single-agent bevacizumab in advanced HCC patients found that 9% of patients developed gastrointestinal bleeding[45]. Atezolizumab is a humanized monoclonal antibody that targets PD-L1 and prevents its binding to the PD-1 receptor and the B7.1 molecule[50]. It has been approved either as a single agent or in combination with chemotherapy for the treatment of patients with non-small cell lung cancer, small-cell lung cancer, urothelial carcinoma, and breast cancer[51]. The combination of atezolizumab plus bevacizumab demonstrated prolonged progression-free survival in metastatic renal cell carcinoma patients in a phase III trial with an acceptable safety profile[52].

Initial data testing this combination in HCC patients originates from a phase Ib study (NCT02645531) evaluating this combination as first-line therapy in 26 patients with advanced HCC[53]. Approximately 35% of patients developed grade 3-4 toxicities with hypertension being the most frequently reported adverse event, with an ORR of 62%[53]. In late 2019, the study authors reported that patients who received the combination therapy in Arm F demonstrated significantly better median progression-free survival (5.6 *vs* 3.4 mo, *P* = 0.0108) when compared to atezolizumab alone[54]. The most common side effects seen in the patients randomized to combination therapy included proteinuria, fatigue and rash[55]. Patients in Arm A had a median overall survival of 17.1 mo[55].Initial phase III data has been reported from the IMBRAVE 150 trial that randomized approximately 501 systemic treatment-naïve patients with unresectable HCC to receive atezolizumab plus bevacizumab or sorafenib alone[56]. Preliminary data published in November 2019 demonstrated an improved PFS (6.8 *vs* 4.3) and OS hazard ratio (0.58) with the combination *vs* sorafenib alone[56] (Table 2). Recent quality-of-life data from IMbrave150 presented in January 2020 revealed that patients taking atezolizumab plus bevacizumab had delayed time to deterioration of quality-of-life[57]. Patients in the combination arm reported greater time to deterioration of physical functioning, diarrhea, loss of appetite, fatigue, and pain[57] (Table 4).

These data suggest that atezolizumab plus bevacizumab may become an alternative regimen for patients with advanced HCC due to its relatively acceptable toxicity profile when compared to a dual checkpoint inhibitor regimen, and improved efficacy when compared to sorafenib alone. The study remains active[58].

Other active clinical trials evaluating this combination include the NCT04102098 phase III trial, a part of the IMbrave 150 study, which will randomize 662 patients with resectable HCC and a high risk of recurrence to receive atezolizumab plus bevacizumab or surveillance as adjuvant therapy[59] (Table 4). Given the significant improvement in PFS seen when this combination is used as first-line therapy, it may also be successful as adjuvant therapy and reduce the high recurrence rates often seen post-resection[4-5,56,59].A single-arm phase II trial (NCT04180072) will enroll 48 patients with advanced HCC and chronic HBV infection, allowing the investigators to determine whether HBV infection has any significant effect on the safety and effectiveness of atezolizumab plus bevacizumab[60] (Table 4).

***Durvalumab plus bevacizumab***

The results of the studies testing atezolizumab and bevacizumab may be generalizable to other checkpoint inhibitors, such as durvalumab, if used in combination with bevacizumab or other VEGF inhibitors given similar mechanisms of action.The combination of durvalumab plus bevacizumab is being studied in multiple different trials, including the aforementioned phase II study (NCT02519348) in patients with advanced HCC as first-line therapy[38] (Table 3). The phase III EMERALD-2 trial (NCT03847428) will compare durvalumab plus bevacizumab to either durvalumab alone or placebo as adjuvant therapy after either ablation or resection in HCC patients with a high risk of recurrence[61] (Table 4).

***Durvalumab plus ramucirumab***

A phase I trial (NCT02572687) is evaluating the safety of the combination of ramucirumab and durvalumab in patients with advanced gastrointestinal or thoracic malignancies including hepatocellular carcinoma[62]. Although no reported phase II or III trials are currently active, if this combination proves to be safe with a tolerable side-effect profile, further study is warranted based on the results of the REACH-2 trial to determine if this combination is most effective in patients with an AFP greater than 400[10].

***Camrelizumab plus apatinib***

Apatinib is a tyrosine kinase inhibitor of VEGFR2 that binds to its target with ten-fold more affinity than sorafenib, and is currently approved in China for use in advanced gastric cancer patients[63,64].Apatinib has demonstrated a tolerable safety profile with evidence of anti-tumor activity in HCC patients as single-agent therapy[64]. In a murine model of lung cancer, the combination of apatinib and an anti-PD-L1 monoclonal antibody inhibited tumor growth in a synergistic fashion with a notable increase in tumor-infiltrating lymphocytes[65]. The combination of apatinib and camrelizumab was studied in a phase Ia and Ib trial (NCT02942329) that enrolled 43 Chinese patients with various gastrointestinal malignancies, including gastric cancer, esophagogastric junction cancer, and advanced hepatocellular carcinoma[63]. This combination was thought to have a tolerable safety profile, with the most common side-effects being hypertension and an elevated AST[63]. Half of all HCC patients demonstrated a partial response, a response similar in magnitude to results from the initial Phase 1b trial (NCT02715531) testing first-line atezolizumab and bevacizumab[53,63]. Multiple studies are evaluating this combination in distinct HCC patient populations[66-69] (Table 4).A phase II study (NCT04014101) seeks to determine whether camrelizumab plus apatinib is safe and effective in patients with advanced HCC as second-line therapy[66]. Another phase II study (NCT03839550)will determine whether this combination is superior to hepatic arterial infusion of chemotherapy in the adjuvant setting, with recurrence-free survival as the primary endpoint[67]. The phase II TRIPLET study (NCT04191889) will evaluate the safety and efficacy of the combination of FOLFOX chemotherapy infused directly into an artery perfusing the tumors, followed by camrelizumab and apatinib in 84 patients with advanced HCC[68]*.* A phase III study (NCT03764293) evaluating camrelizumab and apatinib as first-line therapy in advanced HCC patients will report both OS and PFS as primary endpoints[69].The aforementioned studies are primarily being carried out in Chinese medical centers, which will limit the external validity of the results and require additional studies before their findings can be generalized to other patient populations[66-69].

**COMBINATION THERAPY WITH CHECKPOINT INHIBITORS PLUS MULTI-TARGETED TYROSINE KINASE INHIBITORS**

Sorafenib, lenvatinib, cabozantinib, and regorafenib all have activity against VEGF receptors and may mitigate the immunosuppressive activity of VEGF[6]. Although the exact mechanisms of action are unclear, TKIs can modulate the immune system[70-72]. Sorafenib decreased the populations of Tregs and CD8+ T cells that expressed PD-1 in the tumors of mice models of HCC[70]. An *in-vitro* study demonstrated that sorafenib could increase effector-T cell activation and inhibit Treg suppression of effector-T cells, albeit at sub-pharmacologic doses[71]. Sorafenib has also been shown to restore the ability of dendritic cells to activate T cells *in vitro*[72]. In mouse models of HCC, lenvatinib demonstrated greater antitumor activity in immunocompetent mice when compared to sorafenib but not in immunodeficient mice, suggesting that the increase in activity may be related to immunomodulatory effects[73].

Given that the mechanism of action of TKIs differs from that of checkpoint inhibitors, pairing a TKI with a checkpoint inhibitor may produce responses that are either additive or synergistic. Additionally, responses to combination therapy with checkpoint inhibitors and TKIs may be more effective than responses to VEGF or VEGFR inhibitors alone because TKIs inhibit multiple distinct signaling pathways. If these combination therapies are proven effective, their safety may be of concern. Common toxicities observed with the various TKIs include diarrhea, skin rashes, fatigue, nausea, elevated aspartate aminotransferase levels, and rash[8,9,11,12]. The side-effect profiles of checkpoint inhibitors partially overlap with those of the TKIs, and it is unclear whether this may lead to greater toxicity when compared to single-agent regimens[13,14,24,31]*.*

***Sorafenib plus checkpoint inhibitors***

The safety and effectiveness of sorafenib plus pembrolizumab as first-line therapy will be evaluated in 27 patients with advanced or metastatic HCC participating in a phase Ib/II study (NCT03211416) by the Roswell Park Cancer Institute[74] (Table 5).One phase II trial (NCT03439891) will study the combination of nivolumab plus sorafenib as first-line therapy in patients with advanced HCC[75] (Table 5). ORR is one of the primary endpoints for both studies[74,75].

***Cabozantinib plus checkpoint inhibitors***

Studies testing treatment regimens involving cabozantinib plus immunotherapy include the aforementioned CheckMate 040 study (NCT01658878), which contains two separate arms in which patients are receiving nivolumab plus cabozantinib and nivolumab and ipilimumab plus cabozantinib[30] (Table 2). Initial data from this portion of the CheckMate 040 study has been reported[76]. Seventy-one patients with advanced HCC who were sorafenib-naïve or who had previously been treated with sorafenib were randomized to receive nivolumab plus cabozantinib or nivolumab plus ipilimumab and cabozantinib[76]. The ORR was 26% *vs* 17% for those who received all three drugs or nivolumab plus cabozantinib, respectively[76] (Table 2). Median PFS was 6.8 for the three-drug regimen arm and 5.5 for the two-drug regimen arm[76] (Table 2). The three-drug regimen caused significantly more toxicity, with 71% of patients in that arm reporting grade 3-4 adverse effects, *vs* 42% of patients in the two-drug arm[76]. Approximately 20% of patients in the three-drug arm discontinued the drug secondary to toxicity, compared with 3% of the patients in the two-drug arm[76]. Although the three-drug regimen demonstrates promise based on these early results, its high rate of toxicity may prohibit widespread adoption as standard-of-care therapy. Other checkpoint inhibitors, such as atezolizumab, are being studied as part of combination regimens involving cabozantinib[76] (Table 5).The phase III COSMIC-312 trial (NCT03755791) will study the combination of cabozantinib and atezolizumab *vs* sorafenib as first-line therapy in a multi-national group of patients with advanced HCC[77] (Table 5).

***Lenvatinib plus checkpoint inhibitors***

A phase 1b trial (NCT03006926) in which 18 patients were given a combination of lenvatinib and pembrolizumab demonstrated an acceptable safety profile, with hypertension and poor appetite reported as the most common adverse effects[78]. One phase II study (NCT03841201) will test the combination of lenvatinib and nivolumab in a cohort of patients from a German medical center with ORR and safety and tolerability measures as the primary endpoints[79] (Table 5). A phase III study (NCT03713593) sponsored by Merck will test the combination of lenvatinib plus pembrolizumab in an international cohort of approximately 750 patients with advanced HCC with PFS and OS as the primary endpoints[80]. Patients will be randomized to receive either lenvatinib plus pembrolizumab or lenvatinib plus placebo[80] (Table 5).

***Regorafenib plus checkpoint inhibitors***

Multiple studies evaluating regorafenib in conjunction with PD-1 inhibitors are active. They include a phase Ib trial sponsored by Bayer[81] that will elucidate the safety profile of regorafenib plus pembrolizumab. Recent results were presented at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium in January 2020[82]. Thirty-five patients had been treated, with 29 in the dose-defining cohort and 6 in the dose-expansion cohort[82]. Fifteen patients had discontinued treatment, with either clinical or radiologic disease progression as the most common reason[82]. Eighty-nine percent of patients experienced grade 3 or 4 treatment-emergent adverse events[82]. The multi-center phase II (GOING) trial (NCT04170556) and the single-center phase II (RENOBATE) trial from South Korea will evaluate the combination of regorafenib and nivolumab as second-line and first-line therapy, respectively[83,84] (Table 5).

**COMBINATION THERAPY WITH CHECKPOINT INHIBITORS PLUS LOCOREGIONAL THERAPIES**

Locoregional therapies can activate the immune system through various mechanisms[85-87].

Treatment with either radiofrequency ablation (RFA) or TACE can stimulate the expansion of T-cells recognizing tumor-associated antigens, while RFA can lead to natural killer cell activation[85-87]. The ability of locoregional therapies to stimulate the immune system makes them potential candidates for an effective combination strategy with checkpoint inhibitors[85-87]. The side-effect profiles of immunotherapy and these locoregional therapies differ significantly, which may lead to relatively low toxicity compared to other combination regimens previously discussed[14,15,31,88,89].

***Checkpoint inhibitors plus ablation***

Patients who will likely be eligible for combination therapies involving ablation will have tumors 3 cm or less with early-stage, BCLC class 0 or A disease who are not candidates for surgical resection[4,5]*.* Although multiple types of ablation exist, RFA is the usual standard of care and adverse eventsmay include intraperitoneal bleeding, intrahepatic abscess, grounding pad burns, bile duct injury, thermal damage to organs in close proximity to the tumor, pneumothorax, pain, and tumor seeding of tissues[4,88]*.* RFA is not optimal for tumors that are larger than 5 cm, numerous with 3 or more lesions, poorly visible *via* ultrasound, or adjacent to structures such as the biliary tree, bowel, and vital organs such as the heart[4,5,90].

Multiple studies evaluating combinations of radiofrequency ablation and immunotherapy are ongoing[91-93] (Table 6). Patients with unresectable HCC underwent treatment with tremelimumab and radiofrequency ablation or chemoablation in a phase I study in which 32 patients were enrolled[91]. A partial response was noted in 5 out of 19 patients, and 12 out of 14 patients with confirmed HCV infection were noted to have a decrease in their viral load, consistent with prior studies involving tremelimumab[22,91]. The phase II clinical trial (NCT02821754) sponsored by the National Cancer Institute (NCI) includes an arm where patients with advanced HCC will receive durvalumab plus tremelimumab and RFA, and another where patients will receive cryoablation in conjunction with the checkpoint inhibitors as second-line therapy[92]. Progression-free survival is the primary outcome[92]. Studies involving pembrolizumab include the IMMULAB phase II study (NCT03753659), which will test the combination of RFA or microwave ablation plus pembrolizumab in 30 patients who had not received prior systemic therapy and report ORR as the primary outcome[93].

***Checkpoint inhibitors plus TACE***

TACE plus immunotherapy may be appropriate for patients with intermediate-stage disease, including those with BCLC class B disease based on current indications for TACE[4]. Some patients who are ineligible for RFA, such as those with larger tumors, multiple lesions, or smaller tumors which cannot be safely ablated may be candidates for TACE[4]. Potential adverse events of TACE therapy include damage to the hepatic artery, bile duct injury, acute liver failure, variceal bleeding*,* and cholecystitis[89,94].Specific protocols for performing TACE may differ, and the types of chemotherapy, embolic agents, and schedule of TACE sessions may vary between institutions, among other factors[89]. This variation in how TACE is performed may lead to variation in side-effect profiles, and could affect the efficacy of combination therapies when compared across medical centers[89].

Multiple studies testing the safety of treatment combinations involving checkpoint inhibitors and TACE are active[95-99] (Table 6). The phase II, single-arm IMMUTACE study from Germany (NCT03572582) will study the effectiveness and safety of nivolumab plus TACE for patients with intermediate-stage HCC who have not received prior systemic therapy or TACE, with ORR as the primary endpoint[95]. The combination of TACE and pembrolizumab will be studied as first-line therapy in the phase I/II, single-arm PETAL trial (NCT03397654), which will report the incidence of adverse effects as the primary outcome measure[96].A phase II clinical trial (NCT03638141) will evaluate the combination of durvalumab plus tremelimumab and drug-eluting bead TACE (deb-TACE) in approximately 90 patients with advanced HCC[97]. Patients with active HCV infection will be excluded, which may hinder the ability to detect any effects of the combination therapy on HCV viral load possibly due to tremelimumab[22,97].The previously mentioned NCT02821754 phase II trial sponsored by the NCI contains an arm in which patients will receive durvalumab plus tremelimumab and TACE[92]. The combination of durvalumab plus bevacizumab and TACE will be evaluated as second-line therapy in a phase II trial (NCT03937830) sponsored by the NCI in 22 patients with advanced HCC[98].The combination of durvalumab, bevacizumab and TACE will be compared to TACE alone or TACE plus durvalumab in the phase III, multi-center EMERALD-1 clinical trial (NCT03778957) which will report PFS as a primary outcome measure[99]. Secondary outcome measures include overall survival[99].

**COMBINATION THERAPY WITH CHECKPOINT INHIBITORS PLUS RADIATION**

The effect of checkpoint inhibitors on T-cells can be amplified by radiation[100]. Radiation therapy (RT) has been shown to induce antitumor immune responses through the formation of antitumor antibodies[100]. RT directed at one tumor site can induce responses in other tumor sites not directly targeted, a phenomenon known as the abscopal effect, which is related to immune system activation[100,102,103]. In mouse models of melanoma, radiation therapy can increase both antigen presentation to T-cells recognizing tumor antigens and infiltration of tumors by those T-cells[101]. RT can increase the expression of MHC-1 (major histocompatibility complex-1) molecules in tumors and increase T-cell and natural killer cell tumor infiltration[102,103]. Stereotactic body radiotherapy (SBRT) can be used to treat early-stage, BCLC A disease that is not amenable to treatment with RFA, and can achieve local control rates of approximately 80% or greater[90].SBRT is a possible alternative treatment option after TACE has been unsuccessful, with local control rates of approximately 87%-99% in multiple studies[90]*.* Adverse events as a result of SBRT may include upper gastrointestinal bleeding from esophageal varices or gastric and duodenal ulcers, and biliary strictures[104].SBRT generally has a more tolerable side-effect profile when compared to TACE, with rates of grade 3 or higher toxicity estimated at 6% to 27% in patients with unresectable HCC who receive SBRT[90,104]*.* If proven safe, SBRT plus immunotherapy could become a reasonable treatment option for HCC patients who are not candidates for RFA or who have failed TACE.

Multiple studies testing the combination of ionizing radiation and immunotherapy are ongoing in patients with unresectable HCC[105-107] (Table 6).One phase I study (NCT03203304) will enroll 50 participants with advanced HCC who will first receive SBRT[105].Patients will be randomized into two arms, one of which will receive nivolumab alone after SBRT, while the second will receive nivolumab and ipilimumab[105].If the results from this study suggest that administering nivolumab plus ipilimumab after SBRT is safe, better responses may be seen with that combination than with nivolumab alone given after SBRT due to the synergistic effects of nivolumab plus ipilimumab[24,28,105]*.* A phase II study (NCT03482102) sponsored by Massachusetts General Hospital will evaluate the safety and efficacy of durvalumab and tremelimumab administered in combination with radiation as second-line therapy[106]. As with prior studies examining durvalumab plus tremelimumab, a central question of the NCT03482102 study is whether this combination will be less toxic than those utilizing nivolumab plus ipilimumab in addition to SBRT, and whether tremelimumab will lower the viral load in patients infected with HCV[22,31,106]. Another phase II study will report the overall response rate after enrolling approximately 30 patients, and treating them with pembrolizumab and SBRT in the second-line setting[107]. Both radiation dosing and the time intervals between radiation treatment and immunotherapy treatment may affect the efficacy of combination therapies, and should be considered when the results of these various studies are available[108].

**FUTURE DIRECTIONS**

***PD-1 and PT-112 inhibitors***

PT-112 is a platinum-based drug of the phosphaplatin class currently under development by Phosphaplatin Therapeutics with reported anti-tumor effects both *in-vivo* and *in-vitro*[109-111].It promotes apoptosis in tumor cells and may have anti-angiogenic effects[110].An *in-vitro* study demonstrated that PT-112 treatment led to increased phosphorylation of a wide variety of targets, including VGFR1, EGFR, and CDC2, suggesting it may have activity against multiple distinct pathways[111].Tumor cells may not be able to evade the drug’s antitumor effects through traditional drug resistance pathways because it binds to transmembrane proteins rather than DNA[110,112]. An *in-vitro* study in ovarian cancer cells demonstrated that cisplatin enters cells more readily than phosphaplatins, and may suggest that phosphaplatin treatment may produce fewer side-effects when compared to cisplatin therapy due to reduced intracellular accumulation[113].A phase I clinical trial involving 62 patients receiving PT-112 (NCT2266745) demonstrated no maximum tolerated dose, with fatigue as the most frequently-reported adverse event[114]. A patient with small cell lung cancer who progressed after prior treatment with both a CTLA-4 inhibitor and PD-1 inhibitor was progression-free at 7.5 mo, while a patient with non-small cell lung cancer who progressed on a PD-1 inhibitor was progression-free at 6 mo, indicating the potential benefit of PT-112 therapy[114]. The ORR was approximately 10.7%[114]*.* A phase I/II trial testing PT-112 in patients with advanced solid tumors, including patients with advanced HCC, remains active[115].The safety and efficacy of combining PD-1 therapy and PT-112 is being explored in a multi-center, non-randomized, phase I/II trial (NCT03409458) by Phosphaplatin Therapeutics that will administer PT-112 in combination with avelumab in patients with solid tumors, not including HCC[116].If combination therapy involving PT-112 and immunotherapy is safe and effective, the natural properties of phosphaplatins may prevent drug resistance, leading to more durable responses. If these regimens are truly less toxic than other combination regimens due to low levels of intracellular accumulation of phosphaplatins, PT-112-based combination therapy may become an alternative option for HCC patients who cannot tolerate other regimens due to adverse effects if it is proven safe[113].

**CONCLUSION**

Although immunotherapy remains a promising strategy for HCC patients with unresectable disease, checkpoint inhibitors used as single-agent therapy produce relatively modest overall response rates without significant improvements in survival[18,19].As we have outlined in this review, a combination treatment strategy pairing checkpoint inhibitors with additional pharmacologic agents, locoregional therapy or radiation therapy may produce greater responses than single-agent immunotherapy. Multiple active clinical trials are underway todetermine which combination strategies can safely produce durable clinical responses, ideally with significant improvements in overall survival and overall response rates.

**REFERENCES**

1 **Bray F**, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin* 2018; **68**: 394-424 [PMID: 30207593 DOI: 10.3322/caac.21492]

2 **Rawla P**, Sunkara T, Muralidharan P, Raj JP. Update in global trends and aetiology of hepatocellular carcinoma. *Contemp Oncol (Pozn)* 2018; **22**: 141-150 [PMID: 30455585 DOI: 10.5114/wo.2018.78941]

3 **White DL**, Thrift AP, Kanwal F, Davila J, El-Serag HB. Incidence of Hepatocellular Carcinoma in All 50 United States, From 2000 through 2012. *Gastroenterology* 2017; **152**: 812-820.e5 [PMID: 27889576 DOI: 10.1053/j.gastro.2016.11.020]

4 **Llovet JM**, Zucman-Rossi J, Pikarsky E, Sangro B, Schwartz M, Sherman M, Gores G. Hepatocellular carcinoma. *Nat Rev Dis Primers* 2016; **2**: 16018 [PMID: 27158749 DOI: 10.1038/nrdp.2016.18]

5 **Forner A**, Llovet JM, Bruix J. Hepatocellular carcinoma. *Lancet* 2012; **379**: 1245-1255 [PMID: 22353262 DOI: 10.1016/S0140-6736(11)61347-0]

6 **Bteich F**, Di Bisceglie AM. Current and Future Systemic Therapies for Hepatocellular Carcinoma. *Gastroenterol Hepatol (N Y)* 2019; **15**: 266-272 [PMID: 31360140]

7 **Food and Drug Administration.** FDA approves ramucirumab for hepatocellular carcinoma 2019. In: U.S. Food and Drug Administration [Internet]. Available from: <https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-ramucirumab-hepatocellular-carcinoma>

8 **Llovet JM**, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Häussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J; SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. *N Engl J Med* 2008; **359**: 378-390 [PMID: 18650514 DOI: 10.1056/NEJMoa0708857]

9 **Kudo M**, Finn RS, Qin S, Han KH, Ikeda K, Piscaglia F, Baron A, Park JW, Han G, Jassem J, Blanc JF, Vogel A, Komov D, Evans TRJ, Lopez C, Dutcus C, Guo M, Saito K, Kraljevic S, Tamai T, Ren M, Cheng AL. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. *Lancet* 2018; **391**: 1163-1173 [PMID: 29433850 DOI: 10.1016/S0140-6736(18)30207-1]

10 **Zhu AX**, Kang YK, Yen CJ, Finn RS, Galle PR, Llovet JM, Assenat E, Brandi G, Pracht M, Lim HY, Rau KM, Motomura K, Ohno I, Merle P, Daniele B, Shin DB, Gerken G, Borg C, Hiriart JB, Okusaka T, Morimoto M, Hsu Y, Abada PB, Kudo M; REACH-2 study investigators. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet Oncol* 2019; **20**: 282-296 [PMID: 30665869 DOI: 10.1016/S1470-2045(18)30937-9]

11 **Bruix J**, Qin S, Merle P, Granito A, Huang YH, Bodoky G, Pracht M, Yokosuka O, Rosmorduc O, Breder V, Gerolami R, Masi G, Ross PJ, Song T, Bronowicki JP, Ollivier-Hourmand I, Kudo M, Cheng AL, Llovet JM, Finn RS, LeBerre MA, Baumhauer A, Meinhardt G, Han G; RESORCE Investigators. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet* 2017; **389**: 56-66 [PMID: 27932229 DOI: 10.1016/S0140-6736(16)32453-9]

12 **Abou-Alfa GK**, Meyer T, Cheng AL, El-Khoueiry AB, Rimassa L, Ryoo BY, Cicin I, Merle P, Chen Y, Park JW, Blanc JF, Bolondi L, Klümpen HJ, Chan SL, Zagonel V, Pressiani T, Ryu MH, Venook AP, Hessel C, Borgman-Hagey AE, Schwab G, Kelley RK. Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma. *N Engl J Med* 2018; **379**: 54-63 [PMID: 29972759 DOI: 10.1056/NEJMoa1717002]

13 **El-Khoueiry AB**, Sangro B, Yau T, Crocenzi TS, Kudo M, Hsu C, Kim TY, Choo SP, Trojan J, Welling TH Rd, Meyer T, Kang YK, Yeo W, Chopra A, Anderson J, Dela Cruz C, Lang L, Neely J, Tang H, Dastani HB, Melero I. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. *Lancet* 2017; **389**: 2492-2502 [PMID: 28434648 DOI: 10.1016/S0140-6736(17)31046-2]

14 **Zhu AX**, Finn RS, Edeline J, Cattan S, Ogasawara S, Palmer D, Verslype C, Zagonel V, Fartoux L, Vogel A, Sarker D, Verset G, Chan SL, Knox J, Daniele B, Webber AL, Ebbinghaus SW, Ma J, Siegel AB, Cheng AL, Kudo M; KEYNOTE-224 investigators. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. *Lancet Oncol* 2018; **19**: 940-952 [PMID: 29875066 DOI: 10.1016/S1470-2045(18)30351-6]

15 **Prieto J**, Melero I, Sangro B. Immunological landscape and immunotherapy of hepatocellular carcinoma. *Nat Rev Gastroenterol Hepatol* 2015; **12**: 681-700 [PMID: 26484443 DOI: 10.1038/nrgastro.2015.173]

16 **Food and Drug Administration.** FDA grants accelerated approval to nivolumab for HCC previously treated with sorafenib 2017. In: U.S. Food and Drug Administration [Internet]. Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-nivolumab-hcc-previously-treated-sorafenib

17 **HemOnc Today.** FDA approves pembrolizumab for hepatocellular carcinoma, lung cancer indications 2018. In: HemOnc Today [Internet]. Available from: https://www.healio.com/hematology-oncology/lung-cancer/news/print/hemonc-today/%7B36a1e36d-6e3d-4182-a09e-4f97c889281d%7D/fda-approves-pembrolizumab-for-hepatocellular-carcinoma-lung-cancer-indications

18 **Bristol-Myers Squibb.** Bristol-Myers Squibb Announces Results from CheckMate -459 Study Evaluating Opdivo (nivolumab) as a First-Line Treatment for Patients with Unresectable Hepatocellular Carcinoma 2019. In: Bristol-Myers Squibb [Internet]. Available from: https://news.bms.com/press-release/bmy/bristol-myers-squibb-announces-results-checkmate-459-study-evaluating-opdivo-nivol

19 **Finn RS**, Ryoo BY, Merle P, Kudo M, Bouattour M, Lim HY, Breder V, Edeline J, Chao Y, Ogasawara S, Yau T, Garrido M, Chan SL, Knox J, Daniele B, Ebbinghaus SW, Chen E, Siegel AB, Zhu AX, Cheng AL; KEYNOTE-240 investigators. Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial. *J Clin Oncol* 2020; **38**: 193-202 [PMID: 31790344 DOI: 10.1200/JCO.19.01307]

20 **Qin SK,** Ren ZG, Meng ZQ, Chen ZD, Chai XL, Xiong JP, Bai YX, Yang L, Zhu H, Fang WJ, Lin XY, Chen XM, Li EX, Xia Y, Zou JJ. LBA27A randomized multicentered phase II study to evaluate SHR-1210 (PD-1 antibody) in subjects with advanced hepatocellular carcinoma (HCC) who failed or intolerable to prior systemic treatment. *Ann Oncol* 2018. Available from: https://www.onacademic.com/detail/journal\_1000040906706010\_a4d9.html

21 **Wainberg ZA,** Segal NH, Jaeger D, Lee K-H, Marshall J, Antonia SJ, Butler M, Sanborn RE, Nemunaitis JJ, Carlson CA, Finn RS, Jin X, Antal J, Gupta AK, Massard C. Safety and clinical activity of durvalumab monotherapy in patients with hepatocellular carcinoma (HCC). *J Clin Oncol* 2017; **35 (15\_suppl)**: 4071 [DOI: 10.1200/JCO.2017.35.15\_suppl.4071]

22 **Sangro B**, Gomez-Martin C, de la Mata M, Iñarrairaegui M, Garralda E, Barrera P, Riezu-Boj JI, Larrea E, Alfaro C, Sarobe P, Lasarte JJ, Pérez-Gracia JL, Melero I, Prieto J. A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C. *J Hepatol* 2013; **59**: 81-88 [PMID: 23466307 DOI: 10.1016/j.jhep.2013.02.022]

23 **Kudo M,** Finn RS, Edeline J, Cattan S, Ogasawara S, Palmer D, Verslype C, Zagonel V, Fartoux L, Vogal A, Sarker D, Verset G, Chan SL, Knox J, Daniele B, Gurary EB, Siegel AB, Jain L, Cheng AL, Zhu AX. Updated Efficacy and Safety of KEYNOTE-224: A Phase 2 Study of Pembrolizumab in Patients with Advanced Hepatocellular Carcinoma. Abstract presented at: Gastrointestinal Cancers Symposium (ASCO-GI) 2020, January 23-25, 2020; San Francisco, CA, United States

24 **Larkin J**, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, Schadendorf D, Dummer R, Smylie M, Rutkowski P, Ferrucci PF, Hill A, Wagstaff J, Carlino MS, Haanen JB, Maio M, Marquez-Rodas I, McArthur GA, Ascierto PA, Long GV, Callahan MK, Postow MA, Grossmann K, Sznol M, Dreno B, Bastholt L, Yang A, Rollin LM, Horak C, Hodi FS, Wolchok JD. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. *N Engl J Med* 2015; **373**: 23-34 [PMID: 26027431 DOI: 10.1056/NEJMoa1504030]

25 **Motzer RJ**, Tannir NM, McDermott DF, Arén Frontera O, Melichar B, Choueiri TK, Plimack ER, Barthélémy P, Porta C, George S, Powles T, Donskov F, Neiman V, Kollmannsberger CK, Salman P, Gurney H, Hawkins R, Ravaud A, Grimm MO, Bracarda S, Barrios CH, Tomita Y, Castellano D, Rini BI, Chen AC, Mekan S, McHenry MB, Wind-Rotolo M, Doan J, Sharma P, Hammers HJ, Escudier B; CheckMate 214 Investigators. Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma. *N Engl J Med* 2018; **378**: 1277-1290 [PMID: 29562145 DOI: 10.1056/NEJMoa1712126]

26 **Hellmann MD**, Ciuleanu TE, Pluzanski A, Lee JS, Otterson GA, Audigier-Valette C, Minenza E, Linardou H, Burgers S, Salman P, Borghaei H, Ramalingam SS, Brahmer J, Reck M, O'Byrne KJ, Geese WJ, Green G, Chang H, Szustakowski J, Bhagavatheeswaran P, Healey D, Fu Y, Nathan F, Paz-Ares L. Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden. *N Engl J Med* 2018; **378**: 2093-2104 [PMID: 29658845 DOI: 10.1056/NEJMoa1801946]

27 **Hellmann MD**, Paz-Ares L, Bernabe Caro R, Zurawski B, Kim SW, Carcereny Costa E, Park K, Alexandru A, Lupinacci L, de la Mora Jimenez E, Sakai H, Albert I, Vergnenegre A, Peters S, Syrigos K, Barlesi F, Reck M, Borghaei H, Brahmer JR, O'Byrne KJ, Geese WJ, Bhagavatheeswaran P, Rabindran SK, Kasinathan RS, Nathan FE, Ramalingam SS. Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer. *N Engl J Med* 2019; **381**: 2020-2031 [PMID: 31562796 DOI: 10.1056/NEJMoa1910231]

28 **Hodi FS**, Chiarion-Sileni V, Gonzalez R, Grob JJ, Rutkowski P, Cowey CL, Lao CD, Schadendorf D, Wagstaff J, Dummer R, Ferrucci PF, Smylie M, Hill A, Hogg D, Marquez-Rodas I, Jiang J, Rizzo J, Larkin J, Wolchok JD. Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial. *Lancet Oncol* 2018; **19**: 1480-1492 [PMID: 30361170 DOI: 10.1016/S1470-2045(18)30700-9]

29 **Yau T,** Kang Y-K, Kim T-Y, El-Khoueiry AB, Santoro A, Sangro B, Melero I, Kudo M, Hou M, Matilla A, Tovoli F, Knox JJ, He AR, El-Rayes BF, Acosta-Rivera M, Neely J, Shen Y, Baccan C, Dela Cruz CM, Hsu C. Nivolumab (NIVO) + ipilimumab (IPI) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): Results from CheckMate 040. *J Clin Oncol* 2019; **37(15\_suppl)**: 4012 [DOI: 10.1200/JCO.2019.37.15\_suppl.4012]

30 **Bristol-Myers Squibb.** An Immuno-therapy Study to Evaluate the Effectiveness, Safety and Tolerability of Nivolumab or Nivolumab in Combination with Other Agents in Patients with Advanced Liver Cancer. In: ClinicalTrials.gov [Internet]. Bethesda (MD): US National Library of Medicine. Available from: https://ClinicalTrials.gov/show/NCT01658878

31 **El-Khoueiry AB,** Hsu C, Kang Y, Kim T, Santoro A, Sangro B, Melero I, Kudo M, Hou M, Matilla A, Tovoli F, Knox JJ, He AR, El-Rayes B, Acosta-Rivera M, Neely J, Shen Y, Anderson J, Yau T. Safety Profile of Nivolumab Plus Ipilimumab Combination Therapy in Patients With Advanced Hepatocellular Carcinoma in the CheckMate 040 Study. In: Proceedings of the 13th International Liver Cancer Association Conference 2019; Chicago, IL, United States

32 **Bristol-Myers Squibb.** U.S. Food and Drug Administration Accepts for Priority Review Bristol-Myers Squibb’s Application for Opdivo (nivolumab) Plus Yervoy (ipilimumab) Combination for Patients with Previously Treated Advanced Hepatocellular Carcinoma 2019. In: Bristol-Myers Squibb [Internet]. Available at: https://news.bms.com/press-release/corporatefinancial-news/us-food-and-drug-administration-accepts-priority-review-bris-0

33 **Bristol-Myers Squibb.** A Study of Nivolumab in Combination with Ipilimumab in Participants with Advanced Hepatocellular Carcinoma. In: ClinicalTrials.gov [Internet]. Bethesda (MD): U.S. National Library of Medicine. Available from: https://ClinicalTrials.gov/show/NCT04039607

34 **Anderson Cancer Center.** Nivolumab With or Without Ipilimumab in Treating Patients with Resectable Liver Cancer. In: ClinicalTrials.gov [Internet]. Bethesda (MD): U.S. National Library of Medicine. Available from: <https://ClinicalTrials.gov/show/NCT03222076>

35 **Imperial College London.** Safety and Bioactivity of Ipilimumab and Nivolumab Combination Prior to Liver Resection in Hepatocellular Carcinoma. In: ClinicalTrials.gov [Internet]. Bethesda (MD): U.S. National Library of Medicine. Available from: https://ClinicalTrials.gov/show/NCT03682276

36 **National Health Research Institutes,** Taiwan. Nivolumab Plus Ipilimumab as Neoadjuvant Therapy for Hepatocellular Carcinoma (HCC). In: ClinicalTrials.gov [Internet]. Bethesda (MD): U.S. National Library of Medicine. Available from: https://ClinicalTrials.gov/show/NCT03510871

37 **Kelley RK,** Abou-Alfa GK, Bendell JC, Kim T, Borad MJ, Yong W, Morse M, Kang Y, Rebelatto M, Makowsky M, Xiao F, Morris SR, Sangro B. Phase I/II study of durvalumab and tremelimumab in patients with unresectable hepatocellular carcinoma (HCC): Phase I safety and efficacy analyses. *J Clin Oncol* 2017; **35**: 4073 [DOI: 10.1200/JCO.2017.35.15\_suppl.4073]

38 **MedImmune LLC.** A Study of Durvalumab or Tremelimumab Monotherapy, or Durvalumab in Combination with Tremelimumab or Bevacizumab in Advanced Hepatocellular Carcinoma. In: ClinicalTrials.gov [Internet]. Bethesda (MD): U.S. National Library of Medicine. Available from: https://ClinicalTrials.gov/show/NCT02519348

39 **AstraZeneca.** Study of Durvalumab and Tremelimumab as First-line Treatment in Patients with Advanced Hepatocellular Carcinoma. In: ClinicalTrials.gov [Internet]. Bethesda (MD): U.S. National Library of Medicine. Available from: https://ClinicalTrials.gov/show/NCT03298451

40 **Linch SN**, McNamara MJ, Redmond WL. OX40 Agonists and Combination Immunotherapy: Putting the Pedal to the Metal. *Front Oncol* 2015; **5**: 34 [PMID: 25763356 DOI: 10.3389/fonc.2015.00034]

41 **Curti BD**, Kovacsovics-Bankowski M, Morris N, Walker E, Chisholm L, Floyd K, Walker J, Gonzalez I, Meeuwsen T, Fox BA, Moudgil T, Miller W, Haley D, Coffey T, Fisher B, Delanty-Miller L, Rymarchyk N, Kelly T, Crocenzi T, Bernstein E, Sanborn R, Urba WJ, Weinberg AD. OX40 is a potent immune-stimulating target in late-stage cancer patients. *Cancer Res* 2013; **73**: 7189-7198 [PMID: 24177180 DOI: 10.1158/0008-5472.CAN-12-4174]

42 **Guo Z**, Wang X, Cheng D, Xia Z, Luan M, Zhang S. PD-1 blockade and OX40 triggering synergistically protects against tumor growth in a murine model of ovarian cancer. *PLoS One* 2014; **9**: e89350 [PMID: 24586709 DOI: 10.1371/journal.pone.0089350]

43 **Incyte Biosciences International Sàrl.** A Study Exploring the Safety and Efficacy of INCAGN01949 in Combination with Immune Therapies in Advanced or Metastatic Malignancies. In: ClinicalTrials.gov [Internet]. Bethesda (MD): U.S. National Library of Medicine. Available from: https://ClinicalTrials.gov/show/NCT03241173

44 **Incyte Biosciences International Sàrl.** Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies. In: ClinicalTrials.gov [Internet]. Bethesda (MD): U.S. National Library of Medicine. Available from: https://ClinicalTrials.gov/show/NCT03126110

45 **Boige V**, Malka D, Bourredjem A, Dromain C, Baey C, Jacques N, Pignon JP, Vimond N, Bouvet-Forteau N, De Baere T, Ducreux M, Farace F. Efficacy, safety, and biomarkers of single-agent bevacizumab therapy in patients with advanced hepatocellular carcinoma. *Oncologist* 2012; **17**: 1063-1072 [PMID: 22707516 DOI: 10.1634/theoncologist.2011-0465]

46 **Tromp SC**, oude Egbrink MG, Dings RP, van Velzen S, Slaaf DW, Hillen HF, Tangelder GJ, Reneman RS, Griffioen AW. Tumor angiogenesis factors reduce leukocyte adhesion in vivo. *Int Immunol* 2000; **12**: 671-676 [PMID: 10784613 DOI: 10.1093/intimm/12.5.671]

47 **Terme M**, Colussi O, Marcheteau E, Tanchot C, Tartour E, Taieb J. Modulation of immunity by antiangiogenic molecules in cancer. *Clin Dev Immunol* 2012; **2012**: 492920 [PMID: 23320019 DOI: 10.1155/2012/492920]

48 **DAILYMED.** LABEL: AVASTIN- bevacizumab injection, solution. In: DAILYMED [Internet]. Available from: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=939b5d1f-9fb2-4499-80ef-0607aa6b114e

49 **Siegel AB**, Cohen EI, Ocean A, Lehrer D, Goldenberg A, Knox JJ, Chen H, Clark-Garvey S, Weinberg A, Mandeli J, Christos P, Mazumdar M, Popa E, Brown RS Jr, Rafii S, Schwartz JD. Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma. *J Clin Oncol* 2008; **26**: 2992-2998 [PMID: 18565886 DOI: 10.1200/JCO.2007.15.9947]

50 **McDermott DF**, Huseni MA, Atkins MB, Motzer RJ, Rini BI, Escudier B, Fong L, Joseph RW, Pal SK, Reeves JA, Sznol M, Hainsworth J, Rathmell WK, Stadler WM, Hutson T, Gore ME, Ravaud A, Bracarda S, Suárez C, Danielli R, Gruenwald V, Choueiri TK, Nickles D, Jhunjhunwala S, Piault-Louis E, Thobhani A, Qiu J, Chen DS, Hegde PS, Schiff C, Fine GD, Powles T. Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma. *Nat Med* 2018; **24**: 749-757 [PMID: 29867230 DOI: 10.1038/s41591-018-0053-3]

51 **DAILYMED.** LABEL: TECENTRIQ - atezolizumab injection, solution. December 11, 2019. In: DAILYMED [Internet]. Available from: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6fa682c9-a312-4932-9831-f286908660ee

52 **Rini BI**, Powles T, Atkins MB, Escudier B, McDermott DF, Suarez C, Bracarda S, Stadler WM, Donskov F, Lee JL, Hawkins R, Ravaud A, Alekseev B, Staehler M, Uemura M, De Giorgi U, Mellado B, Porta C, Melichar B, Gurney H, Bedke J, Choueiri TK, Parnis F, Khaznadar T, Thobhani A, Li S, Piault-Louis E, Frantz G, Huseni M, Schiff C, Green MC, Motzer RJ; IMmotion151 Study Group. Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial. *Lancet* 2019; **393**: 2404-2415 [PMID: 31079938 DOI: 10.1016/S0140-6736(19)30723-8]

53 **Stein S,** Pishvaian MJ, Lee MS, Lee K, Hernandez S, Kwan A, Liu B, Grossman W, Iizuka K, Ryoo B. Safety and clinical activity of 1L atezolizumab + bevacizumab in a phase Ib study in hepatocellular carcinoma (HCC). *J Clin Oncol* 2018; **36(15\_suppl):** 4074 [DOI: 10.1200/JCO.2018.36.15\_suppl.4074]

54 **Lee M,** Ryoo B-Y, Hsu C-H, Numata K, Stein S, Verret W, Hack S, Spahn J, Liu B, Abdullah H, He R, Lee KH. Randomised efficacy and safety results for atezolizumab (Atezo) + bevacizumab (Bev) in patients (pts) with previously untreated, unresectable hepatocellular carcinoma (HCC). *Annals of Oncology* 2019; **30(Supplement\_5)** [DOI: 10.1093/annonc/mdz394.030]

55 **Targeted Oncology.** Combination of Atezolizumab and Bevacizumab Shows Early Efficacy in Unresectable HCC 2019. In: Targeted Oncology [Internet]. Available from: https://www.targetedonc.com/conference/esmo-2019/combination-of-atezolizumab-and-bevacizumab-shows-early-efficacy-in-unresectable-hcc

56 **Cheng A-L,** Qin S, Ikeda M, Galle P, Ducreux M, Zhu A, Kim T-Y, Kudo M, Breder V, Merle P, Kaseb A, Li D, Verret W, Xu Z, Hernandez S, Liu J, Huang C, Mulla S, Lim HY, Finn R. IMbrave150: Efficacy and safety results from a ph III study evaluating atezolizumab (atezo) + bevacizumab (bev) vs sorafenib (Sor) as first treatment (tx) for patients (pts) with unresectable hepatocellular carcinoma (HCC). *Annals of Oncology* 2019; **30(Supplement\_9)** [DOI: 10.1093/annonc/mdz446.002]

57 **Galle PR,** Finn RS, Qin S, Ikeda M, Zhu AX, Kim T-Y, Kudo M, Breder VV, Merle P, Kaseb AO, Li D, Mulla S, Verret W, Xu D-Z, Hernandez S, Liu J, Huang C, Lim HY, Cheng A-L, Ducreux M. Patient-reported outcomes (PROs) from the Phase III IMbrave150 trial of atezolizumab (atezo) + bevacizumab (bev) vs sorafenib (sor) as first-line treatment (tx) for patients (pts) with unresectable hepatocellular carcinoma (HCC). *J Clin Oncol* 2020; **38(4\_suppl):** 476 [doi: 10.1200/JCO.2020.38.4\_suppl.476]

58 **Hoffmann-La Roche.** A Study of Atezolizumab in Combination With Bevacizumab Compared With Sorafenib in Patients With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma IMbrave150. In: ClinicalTrials.gov [Internet]. Bethesda (MD): U.S. National Library of Medicine. Available from: https://ClinicalTrials.gov/show/NCT03434379

59 **Hoffmann-La Roche.** A Study of Atezolizumab Plus Bevacizumab Versus Active Surveillance as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Surgical Resection or Ablation. In: ClinicalTrials.gov [Internet]. Bethesda (MD): U.S. National Library of Medicine. Available from: https://ClinicalTrials.gov/show/NCT04102098

60 **National Health Research Institutes,** Taiwan. Atezolizumab Plus Bevacizumab With HCC and HBV Infection. In: ClinicalTrials.gov [Internet]. Bethesda (MD): U.S. National Library of Medicine. Available from: https://ClinicalTrials.gov/show/NCT04180072

61 **AstraZeneca.** Assess Efficacy and Safety of Durvalumab Alone or Combined With Bevacizumab in High Risk of Recurrence HCC Patients After Curative Treatment. In: ClinicalTrials.gov [Internet]. Bethesda (MD): U.S. National Library of Medicine. Available from: https://ClinicalTrials.gov/show/NCT03847428

62 **Eli Lilly and Company.** A Study of Ramucirumab (LY3009806) Plus MEDI4736 in Participants With Advanced Gastrointestinal or Thoracic Malignancies.In: ClinicalTrials.gov [Internet]. Bethesda (MD): U.S. National Library of Medicine. Available from: https://ClinicalTrials.gov/show/NCT02572687

63 **Xu J**, Zhang Y, Jia R, Yue C, Chang L, Liu R, Zhang G, Zhao C, Zhang Y, Chen C, Wang Y, Yi X, Hu Z, Zou J, Wang Q. Anti-PD-1 Antibody SHR-1210 Combined with Apatinib for Advanced Hepatocellular Carcinoma, Gastric, or Esophagogastric Junction Cancer: An Open-label, Dose Escalation and Expansion Study. *Clin Cancer Res* 2019; **25**: 515-523 [PMID: 30348638 DOI: 10.1158/1078-0432.CCR-18-2484]

64 **Zhang Y**, Fan W, Wang Y, Huang G, Li J. Apatinib for Patients With Sorafenib-Refractory Advanced Hepatitis B Virus Related Hepatocellular Carcinoma: Results of a Pilot Study. *Cancer Control* 2019; **26**: 1073274819872216 [PMID: 31466465 DOI: 10.1177/1073274819872216]

65 **Zhao S,** Jiang T, Li X, Zhou C. OA11.07 Combining Anti-Angiogenesis and Immunotherapy Enhances Antitumor Effect by Promoting Immune Response in Lung Cancer. *Journal of Thoracic Oncology* 2017; **12(1):** S288 [DOI: 10.1016/j.jtho.2016.11.293]

66 **Shanghai Zhongshan Hospital.** SHR-1210 Plus Apatinib in Patients With Advanced-Stage Hepatocellular Carcinoma. In: ClinicalTrials.gov [Internet]. Bethesda (MD): U.S. National Library of Medicine. Available from: https://ClinicalTrials.gov/show/NCT04014101

67 **Cancer Institute and Hospital CAoMS.** Combine Apatinib Mesylate With PD-1 Antibody SHR-1210 for HCC With High Risk of Recurrence After Radical Resection. In: ClinicalTrials.gov [Internet]. Bethesda (MD): U.S. National Library of Medicine. Available from: https://ClinicalTrials.gov/show/NCT03839550

68 **Sun Yat-sen University.** A Trial of Hepatic Arterial Infusion Combined With Apatinib and Camrelizumab for C-staged Hepatocellular Carcinoma in BCLC Classification. In: ClinicalTrials.gov [Internet]. Bethesda (MD): U.S. National Library of Medicine. Available from: https://ClinicalTrials.gov/show/NCT04191889

69 **Jiangsu HengRui Medicine Co. L.** A Study to Evaluate SHR-1210 in Combination with Apatinib as First-Line Therapy in Patients with Advanced HCC. In: ClinicalTrials.gov [Internet]. Bethesda (MD): U.S. National Library of Medicine. Available from: https://ClinicalTrials.gov/show/NCT03764293

70 **Chen ML**, Yan BS, Lu WC, Chen MH, Yu SL, Yang PC, Cheng AL. Sorafenib relieves cell-intrinsic and cell-extrinsic inhibitions of effector T cells in tumor microenvironment to augment antitumor immunity. *Int J Cancer* 2014; **134**: 319-331 [PMID: 23818246 DOI: 10.1002/ijc.28362]

71 **Cabrera R**, Ararat M, Xu Y, Brusko T, Wasserfall C, Atkinson MA, Chang LJ, Liu C, Nelson DR. Immune modulation of effector CD4+ and regulatory T cell function by sorafenib in patients with hepatocellular carcinoma. *Cancer Immunol Immunother* 2013; **62**: 737-746 [PMID: 23223899 DOI: 10.1007/s00262-012-1380-8]

72 **Alfaro C**, Suarez N, Gonzalez A, Solano S, Erro L, Dubrot J, Palazon A, Hervas-Stubbs S, Gurpide A, Lopez-Picazo JM, Grande-Pulido E, Melero I, Perez-Gracia JL. Influence of bevacizumab, sunitinib and sorafenib as single agents or in combination on the inhibitory effects of VEGF on human dendritic cell differentiation from monocytes. *Br J Cancer* 2009; **100**: 1111-1119 [PMID: 19277038 DOI: 10.1038/sj.bjc.6604965]

73 **Kimura T**, Kato Y, Ozawa Y, Kodama K, Ito J, Ichikawa K, Yamada K, Hori Y, Tabata K, Takase K, Matsui J, Funahashi Y, Nomoto K. Immunomodulatory activity of lenvatinib contributes to antitumor activity in the Hepa1-6 hepatocellular carcinoma model. *Cancer Sci* 2018; **109**: 3993-4002 [PMID: 30447042 DOI: 10.1111/cas.13806]

74 **Roswell Park Cancer Institute.** Sorafenib Tosylate and Pembrolizumab in Treating Patients with Advanced or Metastatic Liver Cancer. In: ClinicalTrials.gov [Internet]. Bethesda (MD): U.S. National Library of Medicine. Available from: https://ClinicalTrials.gov/show/NCT03211416

75 **Kelley RK.** Sorafenib and Nivolumab in Treating Participants with Unresectable, Locally Advanced or Metastatic Liver Cancer. In: ClinicalTrials.gov [Internet]. Bethesda (MD): U.S. National Library of Medicine. Available from: https://ClinicalTrials.gov/show/NCT03439891

76 **Yau T,** Zagonel V, Santoro A, Acosta-Rivera M, Choo SP, Matilla A, He AR, Gracian AC, El-Khoueiry AB, Sangro B, Eldawy T, Bruix J, Frassineti G, Vaccaro GM, Tschaika M, Scheffold C, Shen Y, Neely J, Piscaglia F. Nivolumab (NIVO) + ipilimumab (IPI) + cabozantinib (CABO) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): Results from CheckMate 040. *J Clin Oncol* 2020; **38(4\_suppl)**: 478 [DOI: 10.1200/JCO.2020.38.4\_suppl.478]

77 **Exelixis.** Study of Cabozantinib in Combination with Atezolizumab versus Sorafenib in Subjects with Advanced HCC Who Have Not Received Previous Systemic Anticancer Therapy. In: ClinicalTrials.gov [Internet]. Bethesda (MD): U.S. National Library of Medicine. Available from: https://ClinicalTrials.gov/show/NCT03755791

78 **Ikeda M,** Sung MW, Kudo M, Kobayashi M, Baron AD, Finn RS, Kaneko S, Zhu AX, Kubota T, Kraljevic S, Ishikawa K, Siegel AB, Kumada H, Okusaka T. A phase 1b trial of lenvatinib (LEN) plus pembrolizumab (PEM) in patients (pts) with unresectable hepatocellular carcinoma (uHCC). *J Clin Oncol* 2018; **36(15\_suppl)**: 4076 [DOI: 10.1200/JCO.2018.36.15\_suppl.4076]

79 **IKF Klinische Krebsforschung GmbH at Krankenhaus Nordwest.** Immunotherapy with Nivolumab in Combination with Lenvatinib for Advanced Stage Hepatocellular Carcinoma. In: ClinicalTrials.gov [Internet]. Bethesda (MD): U.S. National Library of Medicine. Available from: https://ClinicalTrials.gov/show/NCT03841201

80 **Merck Sharp Dohme Corp.** Safety and Efficacy of Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) Versus Lenvatinib as First-line Therapy in Participants With Advanced Hepatocellular Carcinoma (MK-7902-002/E7080-G000-311/LEAP-002). In: ClinicalTrials.gov [Internet]. Bethesda (MD): U.S. National Library of Medicine. Available from: https://ClinicalTrials.gov/show/NCT03713593

81 **Bayer.** Regorafenib Plus Pembrolizumab in First Line Systemic Treatment of HCC. In: ClinicalTrials.gov [Internet]. Bethesda (MD): U.S. National Library of Medicine. Available from: https://ClinicalTrials.gov/show/NCT03347292

82 **El-Khoueiry AB,** Kim RD, Harris WP, Sung MW, Waldschmidt D, Iqbal S, Zhang A, Nakajima K, Galle PR. Phase 1b study of regorafenib plus pembrolizumab for first-line treatment of advanced hepatocellular carcinoma. Poster presented at: American Society of Clinical Oncology-Gastrointestinal Cancers Symposium 2020; San Francisco, CA, United States

83 **Fundacion Clinic per a la Recerca Biomédica.** Regorafenib Followed by Nivolumab in Patients with Hepatocellular Carcinoma (GOING). In: ClinicalTrials.gov [Internet]. Bethesda (MD): U.S. National Library of Medicine. Available from: https://ClinicalTrials.gov/show/NCT04170556

84 **Asan Medical Center.** Combination of Regorafenib and Nivolumab in Unresectable Hepatocellular Carcinoma. In: ClinicalTrials.gov [Internet]. Bethesda (MD): U.S. National Library of Medicine. Available from: https://ClinicalTrials.gov/show/NCT04310709

85 **Ayaru L**, Pereira SP, Alisa A, Pathan AA, Williams R, Davidson B, Burroughs AK, Meyer T, Behboudi S. Unmasking of alpha-fetoprotein-specific CD4(+) T cell responses in hepatocellular carcinoma patients undergoing embolization. *J Immunol* 2007; **178**: 1914-1922 [PMID: 17237442 DOI: 10.4049/jimmunol.178.3.1914]

86 **Zerbini A**, Pilli M, Laccabue D, Pelosi G, Molinari A, Negri E, Cerioni S, Fagnoni F, Soliani P, Ferrari C, Missale G. Radiofrequency thermal ablation for hepatocellular carcinoma stimulates autologous NK-cell response. *Gastroenterology* 2010; **138**: 1931-1942 [PMID: 20060829 DOI: 10.1053/j.gastro.2009.12.051]

87 **Hiroishi K**, Eguchi J, Baba T, Shimazaki T, Ishii S, Hiraide A, Sakaki M, Doi H, Uozumi S, Omori R, Matsumura T, Yanagawa T, Ito T, Imawari M. Strong CD8(+) T-cell responses against tumor-associated antigens prolong the recurrence-free interval after tumor treatment in patients with hepatocellular carcinoma. *J Gastroenterol* 2010; **45**: 451-458 [PMID: 19936602 DOI: 10.1007/s00535-009-0155-2]

88 **Rhim H**. Complications of radiofrequency ablation in hepatocellular carcinoma. *Abdom Imaging* 2005; **30**: 409-418 [PMID: 15688113 DOI: 10.1007/s00261-004-0255-7]

89 **Pietrosi G**, Miraglia R, Luca A, Vizzini GB, Fili' D, Riccardo V, D'Antoni A, Petridis I, Maruzzelli L, Biondo D, Gridelli B. Arterial chemoembolization/embolization and early complications after hepatocellular carcinoma treatment: a safe standardized protocol in selected patients with Child class A and B cirrhosis. *J Vasc Interv Radiol* 2009; **20**: 896-902 [PMID: 19497762 DOI: 10.1016/j.jvir.2009.03.032]

90 **Xu MJ**, Feng M. Radiation Therapy in HCC: What Data Exist and What Data Do We Need to Incorporate into Guidelines? *Semin Liver Dis* 2019; **39**: 43-52 [PMID: 30536291 DOI: 10.1055/s-0038-1676098]

91 **Duffy AG**, Ulahannan SV, Makorova-Rusher O, Rahma O, Wedemeyer H, Pratt D, Davis JL, Hughes MS, Heller T, ElGindi M, Uppala A, Korangy F, Kleiner DE, Figg WD, Venzon D, Steinberg SM, Venkatesan AM, Krishnasamy V, Abi-Jaoudeh N, Levy E, Wood BJ, Greten TF. Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma. *J Hepatol* 2017; **66**: 545-551 [PMID: 27816492 DOI: 10.1016/j.jhep.2016.10.029]

92 **National Cancer Institute (NCI).** A Pilot Study of Combined Immune Checkpoint Inhibition in Combination with Ablative Therapies in Subjects with Hepatocellular Carcinoma (HCC) or Biliary Tract Carcinomas (BTC). In: ClinicalTrials.gov [Internet]. Bethesda (MD): U.S. National Library of Medicine. Available from: https://ClinicalTrials.gov/show/NCT02821754

93 **Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest.** IMMULAB - Immunotherapy with Pembrolizumab in Combination with Local Ablation in Hepatocellular Carcinoma (HCC). In: ClinicalTrials.gov [Internet]. Bethesda (MD): U.S. National Library of Medicine. Available from: https://clinicaltrials.gov/ct2/show/NCT03753659

94 **Miyayama S**, Yamashiro M, Okuda M, Yoshie Y, Nakashima Y, Ikeno H, Orito N, Notsumata K, Watanabe H, Toya D, Tanaka N, Matsui O. Main bile duct stricture occurring after transcatheter arterial chemoembolization for hepatocellular carcinoma. *Cardiovasc Intervent Radiol* 2010; **33**: 1168-1179 [PMID: 20058008 DOI: 10.1007/s00270-009-9781-6]

95 **AIO-Studien-gGmbH.** Transarterial Chemoembolization in Combination With Nivolumab Performed for Intermediate Stage Hepatocellular Carcinoma. In: ClinicalTrials.gov [Internet]. Bethesda (MD): U.S. National Library of Medicine. Available from: https://ClinicalTrials.gov/show/NCT03572582

96 **Imperial College London.** Study of Pembrolizumab Following TACE in Primary Liver Carcinoma. In: ClinicalTrials.gov [Internet]. Bethesda (MD): U.S. National Library of Medicine. Available from: https://ClinicalTrials.gov/show/NCT03397654

97 **Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.** CTLA-4 PD-L1 Blockade Following Transarterial Chemoembolization (DEB-TACE) in Patients with Intermediate Stage of HCC (Hepatocellular Carcinoma) Using Durvalumab and Tremelimumab. In: ClinicalTrials.gov [Internet]. Bethesda (MD): U.S. National Library of Medicine. Available from: https://ClinicalTrials.gov/show/NCT03638141

98 **National Cancer Institute (NCI).** Combined Treatment of Durvalumab, Bevacizumab, and Transarterial Chemoembolization (TACE) in Subjects With Hepatocellular Carcinoma. In: ClinicalTrials.gov [Internet]. Bethesda (MD): U.S. National Library of Medicine. Available from: https://ClinicalTrials.gov/show/NCT03937830

99 **AstraZeneca.** A Global Study to Evaluate Transarterial Chemoembolization (TACE) in Combination with Durvalumab and Bevacizumab Therapy in Patients with Locoregional Hepatocellular Carcinoma. In: ClinicalTrials.gov [Internet]. Bethesda (MD): U.S. National Library of Medicine. Available from: https://ClinicalTrials.gov/show/NCT03778957

100 **Kalbasi A**, June CH, Haas N, Vapiwala N. Radiation and immunotherapy: a synergistic combination. *J Clin Invest* 2013; **123**: 2756-2763 [PMID: 23863633 DOI: 10.1172/JCI69219]

101 **Lugade AA**, Moran JP, Gerber SA, Rose RC, Frelinger JG, Lord EM. Local radiation therapy of B16 melanoma tumors increases the generation of tumor antigen-specific effector cells that traffic to the tumor. *J Immunol* 2005; **174**: 7516-7523 [PMID: 15944250 DOI: 10.4049/jimmunol.174.12.7516]

102 **Park B**, Yee C, Lee KM. The effect of radiation on the immune response to cancers. *Int J Mol Sci* 2014; **15**: 927-943 [PMID: 24434638 DOI: 10.3390/ijms15010927]

103 **Reits EA**, Hodge JW, Herberts CA, Groothuis TA, Chakraborty M, Wansley EK, Camphausen K, Luiten RM, de Ru AH, Neijssen J, Griekspoor A, Mesman E, Verreck FA, Spits H, Schlom J, van Veelen P, Neefjes JJ. Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy. *J Exp Med* 2006; **203**: 1259-1271 [PMID: 16636135 DOI: 10.1084/jem.20052494]

104 **Sapir E**, Tao Y, Schipper MJ, Bazzi L, Novelli PM, Devlin P, Owen D, Cuneo KC, Lawrence TS, Parikh ND, Feng M. Stereotactic Body Radiation Therapy as an Alternative to Transarterial Chemoembolization for Hepatocellular Carcinoma. *Int J Radiat Oncol Biol Phys* 2018; **100**: 122-130 [PMID: 29066120 DOI: 10.1016/j.ijrobp.2017.09.001]

105 **University of Chicago.** Stereotactic Body Radiotherapy (SBRT) Followed by Immunotherapy in Liver Cancer. In: ClinicalTrials.gov [Internet]. Bethesda (MD): U.S. National Library of Medicine. Available from: https://ClinicalTrials.gov/show/NCT03203304. ClinicalTrials.gov Identifier: NCT03203304

106 **Massachusetts General Hospital.** Durvalumab (MEDI4736) and Tremelimumab and Radiation Therapy in Hepatocellular Carcinoma and Biliary Tract Cancer. In: ClinicalTrials.gov [Internet]. Bethesda (MD): U.S. National Library of Medicine. Available from: https://ClinicalTrials.gov/show/NCT03482102

107 **University Health Network T.** Study of Pembrolizumab and Radiotherapy in Liver Cancer. In: ClinicalTrials.gov [Internet]. Bethesda (MD): U.S. National Library of Medicine. Available from: https://ClinicalTrials.gov/show/NCT03316872

108 **Demaria S**, Coleman CN, Formenti SC. Radiotherapy: Changing the Game in Immunotherapy. *Trends Cancer* 2016; **2**: 286-294 [PMID: 27774519 DOI: 10.1016/j.trecan.2016.05.002]

109 **Phosplatin Therapeutics.** About Phosplatin Therapeutics 2017. In: Phosplatin Therapeutics [Internet]. Available at: http://phosplatin.com/about

110 **National Cancer Institute.** NCI Drug Dictionary. In: National Cancer Institute [Internet]. Available at: https://www.cancer.gov/publications/dictionaries/cancer-drug/def/795706

111 **Tosi D,** Perez-Gracia E, Pourquier P, Ames TD, Wing RA, Jimeno J, Gongora C. Abstract 2378: A kinome analysis of the molecular pharmacodynamics of PT-112 in a human cancer cell line. *Cancer Research* 2017; **77(13 Supplement):** 2378 [DOI: 10.1158/1538-7445.Am2017-2378]

112 **Bose RN**, Moghaddas S, Belkacemi L, Tripathi S, Adams NR, Majmudar P, McCall K, Dezvareh H, Nislow C. Absence of Activation of DNA Repair Genes and Excellent Efficacy of Phosphaplatins against Human Ovarian Cancers: Implications To Treat Resistant Cancers. *J Med Chem* 2015; **58**: 8387-8401 [PMID: 26455832 DOI: 10.1021/acs.jmedchem.5b00732]

113 **Bose RN,** Maurmann L, Mishur RJ, Yasui L, Gupta S, Grayburn WS, Hofstetter H, Salley T. Non-DNA-binding platinum anticancer agents: Cytotoxic activities of platinum–phosphato complexes towards human ovarian cancer cells. *Proceedings of the National Academy of Sciences* 2008; **105(47):** 18314-18319 [DOI: 10.1073/pnas.0803094105]

114 **Karp DD,** Camidge DR, Infante JR, Ames TD, Jimeno JM, Bryce AH, PT-112: A Well-Tolerated Novel Immunogenic Cell Death (ICD) Inducer with Activity in Advanced Solid Tumors. ESMO 2018 Congress 2018. *Ann Oncol* 2018; **29**: viii133-viii148 [DOI: 10.1093/annonc/mdy279]

115 **SciClone Pharmaceuticals.** An Open-label Phase I/II Clinical Trial of PT-112 Injection for Advanced Solid Tumors and Advanced Hepatocellular Carcinoma. In: ClinicalTrials.gov [Internet]. Bethesda (MD): U.S. National Library of Medicine. Available from: https://ClinicalTrials.gov/show/NCT03439761

116 **Phosphaplatin Therapeutics.** A Dose Escalation and Confirmation Study of PT-112 in Advanced Solid Tumors in Combination with Avelumab. In: ClinicalTrials.gov [Internet]. Bethesda (MD): U.S. National Library of Medicine. Available from: https://ClinicalTrials.gov/show/NCT03409458

**Footnotes**

**Conflict-of-interest statement:** Authors declare no conflict of interests for this article.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

**Manuscript source:** Invited manuscript

**Peer-review started:** February 1, 2020

**First decision:** February 24, 2020

**Article in press:**

**Specialty type:** Medicine, research and experimental

**Country/Territory of origin:** United States

**Peer-review report’s scientific quality classification**

Grade A (Excellent): A

Grade B (Very good): 0

Grade C (Good): 0

Grade D (Fair): D

Grade E (Poor): E

**P- Reviewer:** Eskens F, Niu ZS, Wang GY **S- Editor:** Zhang L **L- Editor:** **E- Editor:**

**Table 1 List of systemic therapies utilized in combination therapy**

|  |  |  |
| --- | --- | --- |
| **Drug class** | **List of agents** | **Mechanism of action** |
| PD-1 inhibitors | Nivolumab, Pembrolizumab, Camrelizumab, Tislelizumab | Inhibits PD-1 receptor from binding to PD-L1 |
| PD-L1 inhibitors | Atezolizumab, Durvalumab, Avelumab | Inhibits PD-L1 ligand from binding to PD-1 receptor |
| CTLA-4 inhibitors | Ipilimumab, Tremelimumab | Inhibits CTLA-4 receptor from binding to CD80 or CD86 |
| OX40 agonists | INCAGN01876, INCAGN01949 | Activates OX40 receptor *via* direct binding |
| Multiple tyrosine kinase inhibitors | Sorafenib, Cabozantinib, Lenvatinib, Regorafenib, Apatinib | Inhibits signaling from multiple tyrosine kinases |
| VEGF or VEGFR inhibitors | Ramucirumab, Bevacizumab | Inhibits VEGF interaction with VEGFR |
| Phosphaplatins | PT-112 | Activates tumor cell apoptosis, inhibits angiogenesis |

VEGF: Vascular endothelial growth factor; VEGFR: Vascular endothelial growth factor receptor.

**Table 2 Reported results of successful clinical trials evaluating immunotherapy in hepatocellular carcinoma patients**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Therapy** | **Comparator** | **Therapy indication** | **Phase** | **Approximate data collection period** | **Patients enrolled** | **Primary endpoints** | **Trial identifier** |
| Nivolumab | None | Not specified | I/II | November 26, 2012-August 8, 2016 | 214 (dose-escalation), 48 (dose-expansion) | ORR (dose-escalation phase - 15%), (dose-expansion phase – 20%) | NCT01658878 (CheckMate 040) |
| Pembrolizumab | None | Second-line | II | June 22, 2016- February 20, 2017 | 104 | ORR – 18.3%, median OS 13.2 mo | NCT02702414 (KEYNOTE-224) |
| Camrelizumab | Camrelizumab (regimen 1) *vs* camrelizumab (regimen 2) | Second-line | II | November 15, 2016– November 16, 2017 | 220 | ORR 13.8%, median OS not reached | NCT02989922 |
| Durvalumab | None | Not specified | I/II | August 29, 2012-October 24, 2016 | 40 | ORR – 10.3%, median OS 13.2 mo | NCT01693562 |
| Tremelimumab | None | Not specified | II | December 2008-May 2012 | 21 | ORR - 17.6%, DCR 76.4% | NCT01008358 |
| Pembrolizumab | Placebo | Second-line | III | May 31, 2016-November 23, 2017 | 413 | Median OS 13.9 *vs* 10.6 mo – HR: 0.781; 95%CI: 0.611 to 0.998; *P* = 0.0238, PFS 3.0 *vs* 2.8 mo – HR: 0.718; 95%CI, 0.570 to 0.904; *P* = 0.0022 (pembrolizumab *vs* placebo) | NCT02702401 |
| Nivolumab plus ipilimumab | Nivolumab plus ipilimumab (regimen 1 *vs* regimen 2 *vs* regimen 3) | Second-line | I/II | Minimum follow-up-28 mo at time of data cutoff | 148 | ORR – (32 - Arm A, 31- Arm B, 31 - Arm C), median DOR (17.5 - Arm A, 22.2 - Arm B, 16.6 - Arm C ) | NCT01658878 (CheckMate 040) |
| Durvalumab plus tremelimumab | None | Second-line | I/II | October 19, 2015-January 10, 2017 | 40 | ORR – 15% | NCT02519348 |
| Atezolizumab plus bevacizumab | Sorafenib | First-line | III | March 15, 2018-November 2019 | 501 | OS HR: 0.58 (95%CI: 0.42- 0.79; *P* = 0.0006), PFS 6.8 *vs* 4.3 mo, *P* < 0.0001 (atezolizumab plus bevacizumab *vs* sorafenib) | NCT03434379(IMbrave 150) |

ORR: Overall response rate; OS: Overall survival; DCR: Disease control rate; PFS: Progression-free survival; DOR: Duration of response; OS HR: Overall survival hazard rate.

**Table 3 Summary of active clinical trials evaluating checkpoint inhibitor combination therapy**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Therapy** | **Comparator** | **Therapy indication** | **Phase** | **Estimated study duration** | **Estimated patient enrollment** | **Primary endpoints** | **Trial identifier** |
| Nivolumab plus ipilimumab | None | Neoadjuvant | I/II | March 1, 2019-September 1, 2022 | 32 | Delay to surgery, incidence of treatment-related adverse events | NCT03682276 (PRIME-HCC) |
| Nivolumab plus ipilimumab | Nivolumab *vs* nivolumab plus ipilimumab (regimen 1) *vs* nivolumab plus ipilimumab (regimen 2) | Neoadjuvant | II | September 28, 2017-September 30, 2022 | 45 | Incidence of adverse events | NCT03222076 |
| Nivolumab plus ipilimumab | None | Neoadjuvant | II | June 1, 2018-December 31, 2022 | 40 | Percentage of subjects with tumor shrinkage after therapy | NCT03510871 |
| Nivolumab and ipilimumab plus INCAGN01876 (OX-40 Agonist) | Nivolumab plus INCAGN01876 *vs* ipilimumab plus INCAGN01876 | Not specified | I/II | April 13, 2017-October 28, 2021 | 285 | Safety and tolerability, ORR | NCT03126110 |
| Nivolumab plus ipilimumab | Sorafenib or lenvatinib | First-line | III | September 16, 2019 – September 16, 2023 | 1084 | OS | NCT04039607 (CheckMate 9DW) |
| Durvalumab plus tremelimumab | Durvalumab *vs* tremelimumab *vs* durvalumab plus tremelimumab (regimen 1) *vs* durvalumab plus tremelimumab (regimen 2) *vs* durvalumab plus bevacizumab | Second-line (first-line for patients receiving durvalumab plus bevacizumab) | II | October 19, 2015-January 6, 2021 | 433 | Number patients experiencing adverse events and dose-limiting toxicities | NCT02519348 |
| Durvalumab plus tremelimumab | Durvalumab *vs* durvalumab plus tremelimumab (regimen 1) *vs* durvalumab plus tremelimumab (regimen 2) *vs* sorafenib | First-line | III | October 11, 2017-October 30, 2020 | 1310 | OS | NCT03298451 (HIMALAYA) |

HCC: Hepatocellular carcinoma; ORR: Overall response rate; OS: Overall survival.

**Table 4 Summary of active clinical trials evaluating combination therapy of checkpoint inhibitors plus vascular endothelial growth factor/factor receptor inhibitors**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Therapy** | **Comparator** | **Therapy indication** | **Phase** | **Estimated study duration** | **Estimated patient enrollment** | **Primary endpoints** | **Trial identifier** |
| Atezolizumab plus bevacizumab | None | First-line | II | January 1, 2020-June 30, 2022 | 48 | Best overall response rate | NCT04180072 |
| Atezolizumab plus bevacizumab | Sorafenib | First-line | III | March 15, 2018-June 29, 2022 | 480 | OS, PFS | NCT03434379 (IMbrave 150) |
| Atezolizumab plus bevacizumab | Active surveillance | Adjuvant | III | December 31, 2019-July 12, 2027 | 662 | RFS | NCT04102098 (IMbrave 150) |
| Durvalumab plus bevacizumab | Durvalumab alone *vs* tremelimumab alone *vs* durvalumab plus tremelimumab (regimen 1 *vs* regimen 2) *vs* durvalumab plus bevacizumab | First-line | II | October 19, 2015-January 6, 2021 | 433 | Number patients experiencing adverse events and dose-limiting toxicities | NCT02519348 |
| Durvalumab plus bevacizumab | Durvalumab plus placebo *vs* placebo alone | Adjuvant | III | April 29, 2019-June 16, 2023 | 888 | RFS | NCT03847428  (EMERALD-2) |
| Camrelizumab plus apatinib | None | Second-line | II | June 1, 2019 – October 1, 2020 | 40 | ORR | NCT04014101 |
| Camrelizumab plus apatinib | Hepatic arterial infusion of chemotherapy | Adjuvant | II | February 15, 2019-February 28, 2023 | 200 | RFS | NCT03839550 |
| Camrelizumab plus apatinib and hepatic arterial infusion of FOLFOX chemotherapy regimen | None | Not specified | II | April 13, 2020-December 31, 2025 | 84 | ORR | NCT04191889 |
| Camrelizumab plus apatinib | Sorafenib | First-line | III | June 10, 2019-June 2022 | 510 | OS, PFS | NCT03764293 |

OS: Overall survival; PFS: Progression-free survival; RFS: Recurrence-free survival; ORR: Overall response rate.

**Table 5 Summary of active clinical trials evaluating combination therapy of checkpoint inhibitors plus tyrosine kinase inhibitors**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Therapy** | **Comparator** | **Therapy indication** | **Phase** | **Estimated study duration** | **Estimated patient enrollment** | **Primary endpoints** | **Trial identifier** |
| Nivolumab plus sorafenib | Nivolumab plus sorafenib (regimen 1 *vs* regimen 2) | First-line | II | April 16, 2018-May 31, 2020 | 40 | MTD, ORR | NCT03439891 |
| Pembrolizumab plus sorafenib | None | First-line | Ib/II | September 13, 2017-September 13, 2021 | 27 | ORR | NCT03211416 |
| Nivolumab plus lenvatinib | None | First-line | II | June 12, 2019-October 2021 | 50 | ORR, safety/tolerability | NCT03841201 |
| Pembrolizumab plus lenvatinib | Placebo plus lenvatinib | First-line | III | December 31, 2018-May 13, 2022 | 750 | PFS, OS | NCT03713593 (LEAP-002) |
| Nivolumab plus cabozantinib | Nivolumab plus Ipilimumab plus cabozantinib | Not Specified | I/II | September 26, 2012-April 29, 2022 | 1097 | Safety and tolerability | NCT01658878 (CheckMate 040) |
| Nivolumab plus Ipilimumab plus cabozantinib | Nivolumab plus cabozantinib | Not Specified | I/II | September 26, 2012-April 29, 2022 | 1097 | Safety and tolerability | NCT01658878 (CheckMate 040) |
| Atezolizumab plus cabozantinib | Sorafenib *vs* cabozantinib | First-line | III | December 10, 2018-December 1, 2021 | 740 | Duration of PFS, duration of OS | NCT03755791 (COSMIC-312) |
| Nivolumab plus regorafenib | None | Second-line | I/II | March 16 2020-December 2022 | 60 | Rate of adverse events, rate of death | NCT04170556 (GOING) |
| Nivolumab plus regorafenib | None | First-line | II | May 30, 2020-May 30, 2023 | 42 | Response rate | NCT04310709 (RENOBATE) |

MTD: Maximum tolerated dose; ORR: Overall response rate; PFS: Progression-free survival; OS: Overall survival.

**Table 6 Summary of active clinical trials evaluating combination therapy of checkpoint inhibitors plus ablation, trans-arterial chemoembolization, or radiation**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Therapy** | **Comparator** | **Therapy indication** | **Phase** | **Estimated study duration** | **Estimated patient enrollment** | **Primary endpoints** | **Trial identifier** |
| Pembrolizumab plus RFA or MWA | None | First-line | II | May 9, 2019-September 2022 | 30 | ORR | NCT03753659 (IMMULAB) |
| Durvalumab plus tremelimumab plus RFA | Durvalumab plus tremelimuumab, durvalumab plus tremelimumab plus TACE, or durvalumab plus tremelimumab plus cryoablation | Second-line | II | July 5, 2016, December 31, 2021 | 90 | PFS | NCT02821754 |
| Nivolumab plus TACE | None | First-line | II | June 14, 2018-September 2022 | 49 | ORR | NCT03572582 (IMMUTACE) |
| Pembrolizumab plus TACE | None | First-line | I/II | January 28, 2018-December 31, 2020 | 26 | Incidence of adverse events | NCT03397654 (PETAL) |
| Durvalumab plus tremelimumab plus TACE | Durvalumab plus tremelimuumab, durvalumab plus tremelimumab plus RFA, or durvalumab plus tremelimumab plus cryoablation | Second-line | II | July 5, 2016-December 31, 2021 | 90 | PFS | NCT02821754 |
| Durvalumab plus tremelimumab plus DEB-TACE | Durvalumab plus tremelimumab plus DEB-TACE (regimen 1 vs regimen 2) | Not Specified | II | June 12, 2019-November 2020 | 30 | ORR | NCT03638141 |
| Durvalumab plus bevacizumab plus TACE | Durvalumab plus bevacizumab plus TACE (one TACE procedure *vs* possibility of multiple procedures) | Second-line | II | April 27, 2020-December 31, 2022 | 22 | PFS | NCT03937830 |
| Durvalumab and bevacizumab plus TACE | Durvalumab plus placebo plus TACE *vs* placebo plus TACE | Not specified | III | November 30, 2018-November 29, 2023 | 600 | PFS | NCT03778957 (EMERALD-1) |
| Pembrolizumab plus SBRT | None | Second-line | II | February 15, 2018-April 2, 2022 | 30 | ORR | NCT03316872 |
| Durvalumab plus tremelimumab and radiation | None | Second-line | II | May 14, 2018-October 31, 2025 | 70 | ORR | NCT03482102 |

RFA: Radiofrequency ablation; MWA: Microwave ablation; ORR: Overall response rate; TACE: Transarterial chemoembolization; PFS: Progression-free survival; DEB-TACE: Drug-eluting bead transarterial chemoembolization; SBRT: Stereotactic body radiotherapy.